We are live on
!
Find out more
PSC
Patient Square Capital Portfolio holdings
AUM
$564M
1-Year Est. Return
261.3%
This Fund
S&P 500
This Quarter
Est. Return
+1.86%
1 Year Est. Return
+261.3%
3 Year Est. Return
+328.19%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$267M
AUM Growth
-$2.04M
(-0.76%)
Cap. Flow
-$1.39M
Cap. Flow
% of AUM
-0.52%
Top 10 Holdings %
Top 10 Hldgs %
89.8%
Holding
20
New
9
Increased
9
Reduced
2
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$9.76M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$5.92M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$5.72M |
| 4 |
Geron
GERN
|
+$5.28M |
| 5 |
Allogene Therapeutics
ALLO
|
+$3.67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Liquidia Corp
LQDA
|
+$58.2M |
| 2 |
Pharvaris
PHVS
|
+$715K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$24.5B
| $148M | 55.22% |
12,480,000
+251,535
| +2% | +$2.97M |
|
|
2
Liquidia Corp
LQDA
$7.73B
| $21.9M | 8.18% |
1,860,371
-5,322,161
| -74% | -$58.2M |
|
|
3
Insmed
INSM
$21.4B
| $21.2M | 7.93% |
307,167
+135,463
| +79% | +$9.76M |
|
4
Cullinan Oncology
CGEM
$1.05B
| $10.7M | 4% |
878,897
+54,192
| +7% | +$779K |
|
5
EyePoint Inc
EYPT
$1.04B
| $10.5M | 3.93% |
1,410,331
+48,352
| +4% | +$450K |
|
6
Nurix Therapeutics
NRIX
$2.47B
| $8.41M | 3.14% |
446,296
+120,507
| +37% | +$2.76M |
|
|
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.01M | 2.25% |
+71,990
| New | +$5.92M |
|
8
Enliven Therapeutics
ELVN
$4.15B
| $5.04M | 1.89% |
224,038
+133,466
| +147% | +$3.46M |
|
|
9
Geron
GERN
$860M
| $4.68M | 1.75% |
+1,321,268
| New | +$5.28M |
|
10
Ocular Therapeutix
OCUL
$1.87B
| $4.02M | 1.5% |
470,919
+235,421
| +100% | +$2.3M |
|
|
11
Agios Pharmaceuticals
AGIO
$1.82B
| $4M | 1.5% |
+121,732
| New | +$5.72M |
|
|
12
Pharvaris
PHVS
$2.33B
| $3.98M | 1.49% |
207,603
-34,738
| -14% | -$715K |
|
13
Disc Medicine
IRON
$3B
| $3.58M | 1.34% |
+56,400
| New | +$3.26M |
|
|
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
| $3.37M | 1.26% |
+93,137
| New | +$3.25M |
|
|
15
Allogene Therapeutics
ALLO
$635M
| $3.17M | 1.19% |
+1,489,909
| New | +$3.67M |
|
16
Mirum Pharmaceuticals
MIRM
$6.38B
| $2.68M | 1% |
+64,900
| New | +$2.7M |
|
17
Intellia Therapeutics
NTLA
$1.52B
| $2.52M | 0.94% |
215,981
+87,412
| +68% | +$1.36M |
|
18
Arvinas
ARVN
$590M
| $1.66M | 0.62% |
+86,627
| New | +$2.1M |
|
19
Scholar Rock
SRRK
$5.6B
| $1.38M | 0.52% |
+32,000
| New | +$1.04M |
|
|
ATXS
20
DELISTED
Astria Therapeutics
ATXS
| $939K | 0.35% |
105,057
+65,635
| +166% | +$697K |
|
Similar funds
TCP
AHSW
KF
KBG
AAS
LC
AMCA
OC
Patient Square Capital's Q4 2024 Portfolio in Review
As of Q4 2024, Patient Square Capital held 20 positions worth $267M, down 0.76% from $269M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Patient Square Capital's Q4 2024 filing shows 9 new, 9 increased and 2 reduced positions. Its largest new stake was Intra-Cellular Therapies Inc.: 71,990 shares worth $6.01M. The largest sale was Liquidia Corp, an estimated $58.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Patient Square Capital's largest Q4 2024 buy was Intra-Cellular Therapies Inc.: 71,990 shares worth $6.01M.
- Patient Square Capital added most to Insmed in Q4 2024, an estimated $9.76M increase.
- Patient Square Capital's biggest Q4 2024 reduction was Liquidia Corp, cutting an estimated $58.2M.
- Patient Square Capital's ten largest holdings make up 90% of its $267M portfolio in Q4 2024.
- Patient Square Capital opened 9 new positions and closed 0 in Q4 2024.
- Patient Square Capital's portfolio value fell 0.76% quarter-over-quarter to $267M.
Based on Patient Square Capital's 13F filing for Q4 2024, filed 14 Feb 2025.